Original BioMedicals Cash Flow Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2016
Net Income	-101.51	-75	-59.66	-40.28	-33.88	Upgrade
Depreciation & Amortization	8.83	8.4	8.74	7.94	8.64	Upgrade
Stock-Based Compensation	0.15	0.77	6.72	0.34	-	Upgrade
Other Operating Activities	0.05	-0.05	-	-	-	Upgrade
Change in Accounts Receivable	0.14	-0.52	-0.09	0.04	-0.04	Upgrade
Change in Accounts Payable	2.53	-15.74	18.97	1.15	1.8	Upgrade
Change in Other Net Operating Assets	-6.2	-1.98	-2.17	0.38	-1.45	Upgrade
Operating Cash Flow	-96.01	-84.11	-27.5	-30.42	-24.93	Upgrade
Capital Expenditures	-0.95	-1.84	-0.31	-0.47	-1.92	Upgrade
Investment in Securities	79.75	10.06	-64.87	39.92	-74.85	Upgrade
Other Investing Activities	-	-	0.89	-0.17	-	Upgrade
Investing Cash Flow	78.8	8.22	-64.29	39.28	-76.77	Upgrade
Long-Term Debt Repaid	-4.33	-4.26	-3.85	-3.35	-2.95	Upgrade
Net Debt Issued (Repaid)	-4.33	-4.26	-3.85	-3.35	-2.95	Upgrade
Issuance of Common Stock	3.94	2.92	310.34	-	105.02	Upgrade
Financing Cash Flow	-0.39	-1.34	306.49	-3.35	102.07	Upgrade
Net Cash Flow	-17.6	-77.23	214.7	5.52	0.36	Upgrade
Free Cash Flow	-96.96	-85.95	-27.81	-30.89	-26.86	Upgrade
Free Cash Flow Margin	-25448.29%	-	-64674.42%	-28864.49%	-	Upgrade
Free Cash Flow Per Share	-1.46	-1.30	-0.56	-0.66	-0.65	Upgrade
Cash Interest Paid	0.59	0.87	1.1	1.2	1.39	Upgrade
Levered Free Cash Flow	-60	-60.06	-5.75	-16.41	-14.23	Upgrade
Unlevered Free Cash Flow	-59.63	-59.52	-5.08	-15.66	-13.36	Upgrade
Change in Working Capital	-3.53	-18.23	16.71	1.58	0.31	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.